OUR SCIENCE
Priming tumor microenvironment with regimen,killing cancer cells and consolidating treatment via specified therapy
R&D PIPELINE
xin
Time of issue:2023-02-21 16:41:00
Asset | Modality / Target | Regimen | Indication | Discovery | Pre-Clinical | FIH | POC | Pivotal |
---|---|---|---|---|---|---|---|---|
IN10018 Small molecular FAK inhibitor | + PLD | PROC (double-blind, placebo controlled, randomized study) |
|
|||||
+ MEKi ± IO | IO-failed NRAS melanoma Uveal melanoma |
|
||||||
+ PLD ± IO | PROC, TNBC, HNSCC |
|
||||||
+ chemotherapy + IO | IO-failed NSCLC (randomized study) |
|
||||||
+ chemotherapy + IO bispecific | Pancreatic cancer |
|
||||||
+ KRASG12C inhibitor | KRASG12CCRC and NSCLC |
|
||||||
+3rd EGFR inhibitor | EGFR mutant NSCLC |
|
||||||
OMTX705 | ADC Targeting FAP | Mono / Combo | Solid Tumor |
|
||||
INES103 | Antibody Target undisclosed | Combo | Solid Tumor |
|
||||
IN30718 | ADC Target undisclosed | Mono | Solid Tumor |
|
||||
IN30728 | ADC Target undisclosed | Mono | Solid Tumor |
|
||||
IN20019 | Small molecular Target undisclosed | Mono | Solid Tumor |
|
LATEST NEWS
2023-12-20
2023-10-25
InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023
2023-10-19
InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline
2022-03-17
BioWorld:Inxmed raises $50M to develop cancer therapy in the US, China
2019-06-20
Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009
2019-07-29
Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.